Entering text into the input field will update the search result below

Aadi Bioscience: Commercial Stage With Large Market In Label Expansion

Mar. 06, 2023 11:10 PM ETAadi Bioscience, Inc. (AADI)5 Comments


  • AADI is a commercial stage company with a potential label expansion ahead.
  • It is adequately funded, run by expert management, and has a major catalyst next year.
  • All told, AADI looks good.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »

FDA written on wooden cube with keyboard , calculator, chart,glasses.Business concept

Iryna Drozd

Aadi Bioscience (NASDAQ:AADI) is a commercial stage oncology drug developer working with the mTOR pathway. Lead asset FYARRO (nab-sirolimus) is an albumin-bound sirolimus approved for advanced malignant PEComa (perivascular epithelioid cell tumors), a type of rare cancer occurring in the soft

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-

Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 

This article was written by

Avisol Capital Partners profile picture

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (5)

biogenius profile picture
1. Can the author or anyone comment on the patent issue? I believe the main patent expires on 2029 and that they have applied for extension. If correct, is that adequate protection?
2. On slide 18 of Corporate Presentation, it mentions that preliminary result is expected 1H23. It seems early considering that they started enrolling only March 2022.
@biogenius the language changed to "A pre-planned interim analysis on 40 patients with appropriate follow-up is expected by the end of 2023" in the recent earnings call........
For some reason I guess you saw no need to address the resignation of the AADI CEO last Friday with the resulting 20% drop in the stock in the past two days. I'm guessing you think that was not a material event for the company when the market evidently thinks differently.
Avisol Capital Partners profile picture
@jrnpanther Article was written before he chose to resign. However if you follow the company and Mr Desai you will know it was a constructive transition.
rppearson profile picture
A good read, thanks!
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.